Related Experiment Videos
Administering Esomeprazole as a Continuous Subcutaneous Infusion in the Palliative Demographic: A Retrospective
Jonathan Hindmarsh1, Emma McDonald1, Jonathan Pickard1
1Specialist Centre for Palliative Care, St. Benedict's Hospice, Sunderland, UK.
None:
To evaluate the safety, feasibility, and effectiveness of esomeprazole via continuous subcutaneous infusion, in palliative care patients unable to tolerate oral acid suppression therapy. A retrospective review of 92 prescriptions in 76 patients receiving 24-h esomeprazole via continuous subcutaneous infusion was undertaken. Electronic records were examined for dose, duration, infusion characteristics, site reactions, indications, and symptom outcomes. Across 637 treatment days, esomeprazole was well tolerated, only two patients developed injection site reactions (1%). Symptomatic benefit was observed in over 70% of cases for symptoms relating to dyspepsia, malignant bowel obstruction, and gastrointestinal bleeding. Esomeprazole as a continuous subcutaneous infusion appears safe, feasible, and clinically beneficial. Further prospective studies are warranted.
Related Concept Videos
Oral Drug Delivery Systems: Continuous-Release Systems
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
IV Infusion to Oral Dosing: Conversion Methods
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drug Dosing: Obese Patients